New research is reviving interest in digoxin, an inexpensive and decades-old heart medicine. But the evidence is more nuanced than headlines suggesting a 25% reduction in hospitalizations—and patients should not start or stop the drug without medical guidance.
Researchers studying digoxin and related digitalis drugs say the medications may have a useful role in reducing worsening heart failure and hospitalizations when added to modern treatment.
That is potentially important because digoxin is inexpensive, widely known and has been used in cardiovascular medicine for decades.
But there is a major caveat.
The strongest new evidence does not show that digoxin reduces the risk of death. And the newest randomized trial of low-dose digoxin, published in Nature Medicine, did not find a statistically significant reduction in its primary combined outcome of worsening heart failure events and cardiovascular death.
So what should patients and families actually take from the research?
The short answer is this:
Low-dose digoxin may help some people with heart failure experience fewer worsening episodes and hospitalizations, but it is not a replacement for today’s standard heart-failure treatments, and it requires careful medical supervision.
What is digoxin?
Digoxin is one of the oldest medicines used in cardiovascular care.
It can affect the strength of the heart’s contractions and slow certain excessively fast heart rhythms. Because digoxin can accumulate in the body and become dangerous at excessive levels, doctors may monitor blood concentrations and adjust the dose. The American Heart Association lists digoxin among medications that may be used in selected people with heart failure and notes that blood testing is needed because excessive levels can cause serious side effects.
Digoxin is therefore not a new treatment.
What is new is the effort to understand whether carefully dosed digoxin still has a useful role alongside the much broader treatment options available to heart-failure patients today.
Why is digoxin back in the conversation?
A major reason is a 2026 randomized clinical trial called DECISION.
Researchers enrolled 1,001 people with symptomatic chronic heart failure and a left-ventricular ejection fraction of 50% or less. Participants received either low-dose digoxin or placebo on top of contemporary guideline-recommended treatment.
The researchers targeted a serum digoxin concentration of 0.5 to 0.9 ng/mL, reflecting the low-dose strategy being investigated. Participants were followed for a median of 36.5 months.
The primary outcome included worsening heart-failure events, hospitalizations or urgent visits, as well as cardiovascular death.
There were fewer primary-outcome events numerically among patients receiving digoxin than among those receiving placebo.
But the difference did not reach statistical significance.
That means the trial by itself does not establish that low-dose digoxin reduces the primary outcome.
This is an important distinction from some of the more dramatic headlines surrounding the research.
Then where does the 25% figure come from?
The 25% figure comes from a separate JAMA meta-analysis that pooled results from three large randomized trials involving 9,013 patients treated with digitalis glycosides or placebo.
The analysis found that digitalis glycosides were associated with a 15% lower risk of the combined outcome of cardiovascular death or first worsening-heart-failure event.
The reduction was driven primarily by worsening heart failure.
For the first worsening-heart-failure event, the hazard ratio was 0.75, meaning the relative risk was about 25% lower in the digitalis group.
That sounds dramatic, and it is clinically meaningful, but readers need to understand what “25% lower risk” means.
It does not mean that 25 out of every 100 patients who would otherwise be hospitalized will definitely avoid hospitalization.
The pooled analysis reported first worsening-heart-failure events in about 26% of patients receiving digitalis glycosides compared with 33% of those receiving placebo.
That is an absolute difference of roughly 7 percentage points.
This distinction between relative and absolute risk is important whenever a medical study produces a large percentage headline.
Did the drugs reduce deaths?
This is where the story becomes more complicated.
The pooled analysis did not find a statistically significant reduction in mortality.
The benefit appeared to come primarily from fewer worsening-heart-failure events rather than from people living longer.
That matters because heart failure can become a cycle of worsening symptoms, emergency care and hospitalization.
Preventing those episodes can still be valuable.
But it is different from demonstrating that a medication reduces the risk of death.
For patients and families, those are two separate questions:
Can this treatment help keep someone from getting sick enough to need hospital care?
And:
Can this treatment help someone live longer?
The current evidence provides more encouraging answers to the first question than the second.
Is digoxin replacing newer heart-failure medicines?
No.
That is another important point.
Modern treatment for heart failure with reduced ejection fraction includes several medication classes, including SGLT2 inhibitors and other guideline-directed therapies.
The American Heart Association, American College of Cardiology and Heart Failure Society of America already identify digoxin as a potential additional therapy for certain patients with symptomatic heart failure with reduced ejection fraction despite guideline-directed treatment, or for patients who cannot tolerate that treatment. The guideline says digoxin may be considered to decrease heart-failure hospitalizations.
The new research therefore isn’t discovering a forgotten replacement for modern heart medicine.
Instead, it is asking whether an old drug can still provide an additional benefit when used alongside contemporary treatment.
That is a much more measured, and potentially more useful, finding.
Why does the drug’s low cost matter?
Digoxin has another characteristic that makes researchers and patients interested: it is inexpensive compared with many newer therapies.
That does not make it automatically better.
But medication cost can matter when people struggle to afford long-term treatment.
For families already balancing housing, food, transportation and medical expenses, an inexpensive medication that can safely reduce worsening heart failure could have meaningful value if a doctor determines that it is appropriate.
The important word is if.
A low price does not eliminate the need for the right diagnosis, dose, monitoring and follow-up.
And the new studies do not establish that every person with heart failure should receive digoxin.
Why might this matter to Latino patients and families?
The new digoxin research did not demonstrate a special benefit for Latino patients, so Parriva should not claim that it did.
But heart failure and access to effective treatment are legitimate Latino health concerns.
Research on Hispanic and Latino patients hospitalized with heart failure has found differences in age, risk factors and hospitalization patterns compared with other populations.
Salud America has also highlighted concerns about heart-failure outcomes and access to appropriate care among Latinos.
That makes affordability and access worth discussing. California’s changing health-care access landscape
But an inexpensive drug only helps if patients can actually receive appropriate care, understand how to take it, obtain monitoring when needed and communicate effectively with their health-care team.
For Parriva readers, that is an important distinction.
The question isn’t simply whether a drug is cheap. It’s whether the right patient can safely access the right treatment.
Is digoxin safe?
Digoxin can be safe when appropriately prescribed and monitored, but it is not a medicine people should experiment with on their own.
The DECISION trial used a specific low-dose strategy and monitored blood concentrations. Researchers reported that low-dose digoxin was generally well tolerated in the study.
The American Heart Association notes that excessive digoxin levels can cause problems including nausea, vomiting, appetite loss and potentially dangerous heart-rhythm abnormalities.
That is why the new research should not be interpreted as an invitation for patients to ask for a specific dose or to restart an old prescription.
It is evidence for doctors and researchers to consider, not a personal treatment plan.
What about people already taking digoxin?
The new evidence also raises a caution about stopping the drug automatically.
Researchers conducted a separate analysis following patients after randomized treatment ended and found signs of worsening heart-failure status among some patients who stopped low-dose digoxin.
That finding does not prove that every patient taking digoxin should remain on it.
It does reinforce a simpler message:
Patients taking digoxin should not stop it suddenly or change their dose without talking with their health-care professional.
Medication changes should account for the patient’s heart function, symptoms, other medicines, kidney function, heart rhythm and other individual factors.
What should patients ask their doctor?
If you or a family member has heart failure, the new research may be worth discussing with a clinician; but it should be a conversation, not a reason to change treatment independently.
Useful questions include:
“Is digoxin appropriate for my type of heart failure?”
“What are the potential benefits for me?”
“Would it be added to my current treatment or replace something else?”
“Would I need blood-level monitoring?”
“How would my kidney function or other medications affect the dose?”
“What symptoms should make me call you?”
Those questions are more useful than simply asking whether digoxin is a “miracle drug.”
The renewed interest in digoxin is real.
A 2026 JAMA meta-analysis of 9,013 patients across three randomized trials found that digitalis glycosides were associated with a lower risk of cardiovascular death or first worsening-heart-failure events, with the benefit driven mainly by fewer worsening-heart-failure events.
But the newest low-dose digoxin trial, DECISION, did not produce a statistically significant reduction in its primary combined endpoint.
The evidence also does not establish a mortality benefit from digoxin.
So the most accurate takeaway is not that a 10-cent drug has suddenly solved heart failure.
It is that researchers are finding renewed evidence that a carefully dosed, inexpensive and very old medicine may have a useful role as an additional treatment for selected people with heart failure.
For patients, the practical lesson is equally important:
Do not start, stop or change digoxin based on a headline.
If you have heart failure, ask your doctor whether the new evidence changes anything about your treatment options.
And if medication cost is making it difficult to stay on your treatment plan, tell your health-care team. Cost is a medical issue too, and there may be safer ways to address it than simply skipping doses.
